期刊文献+

瑞舒伐他汀钙抑制尼古丁诱导的人脐静脉内皮细胞基质金属蛋白酶2的表达 被引量:2

Inhibiting effects of rosuvastatin on the expression of matrix metalloproteinase-2 induced by nicotine in human umbilical vein endothelial cells
原文传递
导出
摘要 目的探讨瑞舒伐他汀钙对尼古丁诱导人脐静脉内皮细胞(HUVEC)基质金属蛋白酶2(MMP2)表达的影响。方法取健康剖腹产孕妇的HUVEC进行培养,选择2~4代细胞进行实验(n=5)。分别采用不同浓度(0、1、10、100/μmol/L)尼古丁进行24h处理以及采用100μmol/L尼古丁进行不同时间(0、6、12、24、48h)处理,处理后细胞进行半定量RT-PCR,Western blot检测MMP-2mRNA及蛋白的表达(n=5);内皮细胞首先用系列浓度(2,4,7,10/μg/L)瑞舒伐他汀钙进行预孵育12h,然后对药物干预后细胞进行100μmol/L尼古丁处理24h(n=50)。结果尼古丁呈浓度及时间依赖性诱导HuVEc中MMP-2表达:MMP2表达随尼古丁浓度增加而升高;尼古丁诱导MMP2表达随时间延长而增加。瑞舒伐他汀钙可浓度依赖性地抑制尼古丁诱导的MMP-2的表达[mRNA水平:2、4、7、10μg/L抑制率分别为8.6%、42.5%、66.9%、80.3%,均P〈0.05;蛋白水平:2、4、7、10μg/L抑制率分别为10.6%、37.6%、74.1%、88.2%,均P〈0.051。结论尼古丁是诱导HUVEC中MMP表达的重要因素;瑞舒伐他汀钙能够抑制该进程,且具有剂量依赖性。 Objective To explore the effect of rosuvastatin on the expression of matrix metalloproteinase-2(MMP2 ) in human umbilical vein endothelial cells (HUVEC) induced by nicotine. Methods HUVEC were isolated from umbilical cords of healthy caesarean women and cells at passages 2-4 were used in this study (n= 5). Cells were treated with different concentration of nicotine (0, 1, 10, 100 μmol/L) for 24 h or treatd with 100 μmol/L for different time (0, 6, 12, 24, 48 h), and then the expression of MMP-2 mRNA and protein in cells of the two groups were detected using semiquantitative real time PCR and Western blot ( n=5). Cells were incubated in series concentration rosuvastatin calcium (2, 4, 7, 10 μg/L) for 12 h, and then the incubated cells were treated with 100 μmol/L nicotine for 24 h after pharmacologic interventions (n 5). Results HUVEC MMP 2 expression was induced by nicotine in a concentration-dependent and time-dependent manner. The expression of MMP-2 induced by nicotine was inhibited by rosuvastatin calcium in a concentration-dependent [on mRNA level: the inhibition rates of 2, 4, 7, 10 μg/L were 8.6%, 42.5%, 66.9% and 80.3% respectively, all P〈0.05; on protein level: the inhibition rates of 2, 4, 7, 10μg/L were 10. 6%, 37.6%, 74.1%, 88.2% respectively, all P.〈0. 05]. Conclusion Nicotine is a major factor which can induce the expression of MMP-2 in HUVEC, which is a dangerous pathogenic factor in smoking. Rosuvastatin calcium can inhibit the process in a dose dependent manner.
出处 《中华高血压杂志》 CAS CSCD 北大核心 2013年第11期1066-1070,共5页 Chinese Journal of Hypertension
关键词 尼古丁 脐静脉内皮细胞 基质金属蛋白酶 瑞舒伐他汀钙 Nicotine Human umbilical vein endothelial cells Matrix metalloproteinase Rosuvastatin calcium
  • 相关文献

参考文献1

二级参考文献6

  • 1Kish L (1965). Survey Sampling, Wiley and Sons, New York. 被引量:1
  • 2Gabler S Haeder S and Lahiri P (1999). A model based justification of Kish's formula for design effects for weighting and clustering. Survey Methodology, 250), 105-106. 被引量:1
  • 3Global Tobacco Surveillance System (GTSS) (2009). Global Adult Tobacco Survey (GATS): Sample Design Manual. 被引量:1
  • 4SAS Institute Inc, SAS 9.1.3 Help and documentation, Cary, NC: SAS Institute Inc, 2000-2004. 被引量:1
  • 5SPSS Inc, PASW Statistics 18 Command Syntax Reference, Chicago, IL: SPSS Inc,1993-2007. 被引量:1
  • 6Research Triangle Institute, SUDAAN Language Manual, Release 10.0 Research Triangle Park, NC: Research Triangle Institute, 2008. 被引量:1

共引文献3

同被引文献27

  • 1PAICE J A, FERRELL B. The management of cancer pain [ J]. CA Cancer JChin, 2011, 61 (3): 157-182. 被引量:1
  • 2LI W, LI Y, ZHU S, et al. Rosuvastatin attenuated the existing morphine tolerance in rats with I5 spinal nerve transection through inhibiting activation of astrocytes and phosphorylation of ERK42/44 [J]. NeurosciLett, 2015, 584: 314-319. 被引量:1
  • 3LI Y, SHU Y, JI Q, et al, Attenuation of morphine analgesic tolerance by rosuvastatin in naive and morphine tolerance rats [ J]. Inflammation, 2015, 38 (1) : 134 - 141. 被引量:1
  • 4JIMENEZ ANDRADE J M, MANTYH P. Cancer pain: from the development of nonse models to human clinical trials [ M ] //KRUGERL, LIGHT A R. Translational pain research: from mouse to man. Boca Raton, FL: CRC Press, 2010: 414-420. 被引量:1
  • 5MANTYH P W. Bone cancer pain: from mechanism to therapy [ J] Curr Opin Support Palliat Care, 2014, 8 (2) : 83 -90. 被引量:1
  • 6LEONCINI M, TOSO A, MAIOLI M, et al. Early high - dose rosuvastatin for contrast - induced nephropathy prevention in acute coronary syndrome : results from the PRATO - ACS study ( protective effect of rosuvastatin and antiplatelet therapy on contrast - inducedacute kidney injury and myocardial damage in patients with acute coronary syndrome) [ J]. J Am Coll Cardiol, 2014, 63 (1): 71-79. 被引量:1
  • 7HAN Y, ZHU G, HAN L, et al. Short - term rosuvastatin therapyfor prevention of contrast - induced acute kidney injury in patients with diabetes and chronic kidney disease [ J]. J Am Coll Cardiol, 2014, 63 (1): 62-70. 被引量:1
  • 8ABACI O, ARAT OZKAN A, KOCAS C, et al. Impact of Rosuvastatin on contrast - induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography [ J ]. Am J Cardiol, 2015, 115 (7): 867-871. 被引量:1
  • 9JOYT R, ZOU GY, MAHON J L.N-of-1 (single-patient) trials for statin-related myalgia [ J]. Ann Intern Med, 2014, 161 (7) : 531 -532. 被引量:1
  • 10WOOLTORTON E. Rosuvastatin (Crestor) and rhabdomyolysis [ J]. CMAJ, 2004, 171 (2): 129. 被引量:1

二级引证文献55

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部